Table 4.

Summary of patient outcomes in those patients who achieved a clinical response/benefit to PD-1/PD-L1 blockade

ORR to PD-1/PD-L1, N (%)Time on therapy, median (range; months)TTP from the date of treatment cessation, months (CI)aOngoing TTP from the date of treatment cessation, N (%)TTP from the date of treatment cessation ≥ 6 months, N (%)
12 (63.2%)5.5 (0.7–46.5)18.4 (4.7–54.3)9 (47.4%)13 (68.4%)
  • ORR, objective response rate by RECIST (rest had SD with tumor shrinkage).

  • aPer Kaplan–Meier estimation.